MV Capital Management Inc. Sells 1,254 Shares of Medtronic PLC $MDT

MV Capital Management Inc. trimmed its position in shares of Medtronic PLC (NYSE:MDT) by 6.7% during the second quarter, Holdings Channel.com reports. The firm owned 17,529 shares of the medical technology company’s stock after selling 1,254 shares during the period. MV Capital Management Inc.’s holdings in Medtronic were worth $1,528,000 as of its most recent SEC filing.

Other hedge funds have also bought and sold shares of the company. 1248 Management LLC bought a new position in shares of Medtronic in the first quarter valued at $26,000. Twin Tree Management LP acquired a new stake in shares of Medtronic in the 1st quarter worth about $29,000. Activest Wealth Management raised its holdings in shares of Medtronic by 3,577.8% in the 1st quarter. Activest Wealth Management now owns 331 shares of the medical technology company’s stock worth $30,000 after acquiring an additional 322 shares during the last quarter. Investment Management Corp VA ADV lifted its position in Medtronic by 144.2% in the 1st quarter. Investment Management Corp VA ADV now owns 403 shares of the medical technology company’s stock valued at $36,000 after acquiring an additional 238 shares in the last quarter. Finally, GFG Capital LLC acquired a new position in Medtronic during the 2nd quarter valued at about $36,000. Institutional investors and hedge funds own 82.06% of the company’s stock.

Medtronic Price Performance

Medtronic stock opened at $95.79 on Thursday. The firm has a market capitalization of $122.86 billion, a P/E ratio of 26.39, a PEG ratio of 2.42 and a beta of 0.77. Medtronic PLC has a one year low of $79.29 and a one year high of $99.37. The company has a debt-to-equity ratio of 0.54, a current ratio of 2.01 and a quick ratio of 1.50. The business has a fifty day moving average price of $94.31 and a 200-day moving average price of $90.22.

Medtronic (NYSE:MDT) last issued its earnings results on Tuesday, August 19th. The medical technology company reported $1.26 EPS for the quarter, topping the consensus estimate of $1.23 by $0.03. Medtronic had a return on equity of 14.61% and a net margin of 13.63%.The business had revenue of $8.58 billion during the quarter, compared to the consensus estimate of $8.37 billion. During the same quarter last year, the company earned $1.23 EPS. The firm’s revenue was up 7.7% compared to the same quarter last year. Medtronic has set its FY 2026 guidance at 5.600-5.660 EPS. As a group, equities research analysts forecast that Medtronic PLC will post 5.46 EPS for the current year.

Analysts Set New Price Targets

Several analysts have recently commented on MDT shares. Royal Bank Of Canada reissued an “outperform” rating and issued a $111.00 price objective on shares of Medtronic in a research note on Friday, October 10th. Needham & Company LLC restated a “hold” rating on shares of Medtronic in a research note on Thursday, August 14th. Daiwa Capital Markets lifted their price objective on shares of Medtronic from $101.00 to $104.00 and gave the stock a “buy” rating in a report on Friday, September 12th. UBS Group increased their target price on shares of Medtronic from $94.00 to $95.00 and gave the company a “neutral” rating in a report on Wednesday, August 20th. Finally, Sanford C. Bernstein restated an “outperform” rating and set a $98.00 price target on shares of Medtronic in a report on Friday, October 31st. One equities research analyst has rated the stock with a Strong Buy rating, twelve have issued a Buy rating, nine have given a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $102.82.

Insiders Place Their Bets

In other Medtronic news, EVP Harry Skip Kiil sold 8,605 shares of the firm’s stock in a transaction dated Wednesday, September 3rd. The stock was sold at an average price of $91.58, for a total value of $788,045.90. Following the sale, the executive vice president owned 35,615 shares of the company’s stock, valued at $3,261,621.70. This trade represents a 19.46% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, Director William R. Jellison acquired 2,500 shares of the business’s stock in a transaction dated Monday, August 25th. The shares were acquired at an average cost of $92.37 per share, with a total value of $230,925.00. Following the acquisition, the director directly owned 5,000 shares of the company’s stock, valued at $461,850. This represents a 100.00% increase in their position. The SEC filing for this purchase provides additional information. 0.26% of the stock is owned by insiders.

About Medtronic

Medtronic plc develops, manufactures, and sells device-based medical therapies to healthcare systems, physicians, clinicians, and patients worldwide. Its Cardiovascular Portfolio segment offers implantable cardiac pacemakers, cardioverter defibrillators, and cardiac resynchronization therapy devices; cardiac ablation products; insertable cardiac monitor systems; TYRX products; and remote monitoring and patient-centered software.